prepared by limited proteolysis with pepsin at pH 4.0-4.2 . Fab′ from M15/8 and Mc24/1C6 F(ab′) 2 was produced by reduction with 20 mM 2-mercaptoethanol for 30 min at 25°C, followed by alkylation with excess iodoacetamide.
Measurement of [ 3 H]thymidine incorporation
Cells (5 × 10 4 ) were aliquoted into each well of a 96-well microtitre plate (Gibco) and incubated in 200 µl of supplemented RPMI medium containing the required concentration of mAb for 24 h at 37°C before pulsing overnight with 0.5 µCi [ 3 H]thymidine (Amersham International PLC, UK) in 50 µl RPMI as described previously . The incorporation of [ 3 H]thymidine into DNA was assessed by harvesting the cells onto glass microfibre filters and washing with water. Experimental points were determined in triplicate. The variation between triplicates was less than 10%.
Preparation of anti-Fcµ (M15/8) multimers
M15/8 F(ab′) 3 was prepared using the bis-maleimide crosslinker, o-phenylenedimaleimide, as described by Tutt et al (1991) for the preparation of bispecific trimers.
Hyper-crosslinking experiments
mAb at a concentration of 10 µg ml -1 were first allowed to bind to cells at a concentration of 2.5 × 10 5 ml -1 for 15 min at 4°C. Cells were then separated from excess unbound antibody in the supernatant by centrifugation, and the supernatant removed. Cells were resuspended at a concentration of 2.5 × 10 5 ml -1 in medium containing polyclonal sheep anti-mouse IgG at 20 µg ml -1 , to act as a hyper-crosslinking reagent, plated out as 200 µl aliquots on 96-well microtitre plates, and incubated for 24 h at 37°C before pulsing overnight with 0.5 µCi [ 3 H]thymidine. Cells were then harvested and incorporated radioactivity determined as described above.
Measurement of apoptosis using propidium iodide
Samples were assessed by the method of Nicoletti et al (1991) . Briefly, aliquots of cells (10 6 ) were centrifuged for 5 min at 500 g and then washed once in phosphate-buffered saline (PBS). The cells were then resuspended in hypotonic fluorochrome solution (50 µg ml -1 propidium iodide (PI), 0.1% (w/v) sodium citrate, 0.1% (w/v) Triton X-100) and incubated in the dark at 4°C overnight or 1 h at room temperature. PI staining of DNA from 10 000 cells was detected on a FACScan flow cytometer (Becton Dickinson) and the proportion of DNA giving fluorescence below the G1/0 peak was taken as a measure of apoptosis.
Agarose gel DNA fragmentation analysis
Following incubation of cells under appropriate conditions, samples containing 1-2 × 10 6 cells were harvested. Twenty microlitres TE-SLS (10 mM EDTA, 50 mM Tris-HCl pH 8.0, 0.5% (v/v) sodium lauryl sarkosinate (SLS, Sigma)) plus 0.5 mg ml -1 proteinase K (Sigma) was then added, and the samples incubated for 1-2 h at 50°C. 10 µl 0.16 mg ml -1 RNase A (Sigma) was added and samples were incubated for a further 1-2 h at 50°C. The temperature of the samples was then increased to 70°C for addition of 10 µl of loading buffer [10 mM EDTA, 1% (w/v) low melting point agarose, 0.25% (w/v) bromophenol blue, 40% (w/v) sucrose]. Samples were loaded into dry wells of 1% (w/v) agarose gels containing 0.5 mg ml -1 ethidium bromide and run either overnight at 30-40 V or for 2-3 h at 80 V, in TAE (89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH8.4). DNA was visualized by UV light.
Radioiodination of antibodies
mAb were trace radiolabelled for binding studies using carrier-free 125 I (Amersham International plc) and IODO-BEADS (Pierce Chemicals Co., Rockford, IL, USA) as the oxidizing reagent. Radioactivity was measured in a Rackgamma spectrometer (LKB). The immunoreactive component of each mAb [ 125 I]IgG preparation was estimated by determining what fraction bound to a large antigen excess as described by Elliot et al (1987) . Typically, mAb were found to contain 50-85% reactive material.
Binding of [ 125 I]mAb to the cell surface
The binding of radiolabelled mAb to cells was determined as described by Elliot et al (1987) . Radiolabelled mAb were serially diluted before incubating with cells (0.5-1.25 × 10 6 ml -1 , final volume 1 ml) in RPMI medium containing 10% FCS for 2 h at 37°C. Endocytosis of cell bound mAb was prevented by inclusion of sodium azide (15 mM) and 2-deoxyglucose (50 mM). The cells were separated from the aqueous phase by centrifugation through a 1.1:1 (vol/vol) mixture of dibutyl phthalate:dioctyl phthalate. Radioactivity was measured in a Rackgamma spectrometer (LKB).
RESULTS

Sensitivity of Burkitt's lymphoma cell lines to anti-BCR induced growth inhibition
In preliminary experiments, eight Burkitt's lymphoma cell lines, Daudi, Bristol-8, MUTU-I, MUTU-61E, Nalm-6, Namalwa, Ramos and Raji, were assessed for their sensitivity to anti-Fcµ mAb in growth assays. The results obtained with the Ramos, MUTU-I, and Daudi lines with the anti-Fcµ mAb M15/8 are shown in Figure 1 . Of the eight lines tested, only Ramos and MUTU-I were sensitive to M15/8, showing a 60-80% inhibition of [ 3 H]thymidine incorporation at a mAb concentration of 10 µg ml -1 ( Figure 1A, B) . Two other anti-Fcµ mAb, Mc41/24G10 and ZL7/5, had similar inhibitory activity on these particular cell lines.
The sensitivity of the eight cell lines to polyclonal anti-µ Ab was also determined. Ramos and Mutu-1 were both highly sensitive to polyclonal anti-µ, giving up to 90% inhibition of [ 3 H]thymidine incorporation at 10 µg ml -1 ( Figure 1A, B) . In addition, the Daudi cell line was sensitive ( Figure 1C ) which, in the light of its insensitivity to anti-Fcµ mAb, was of particular interest and suggested that the extent of crosslinking of the BCR was probably important in determining growth arrest. The other five cell lines were insensitive to polyclonal anti-µ antibody. Four of the cell lines, Nalm-6, Bristol-8, Raji and Namalwa, expressed relatively low to medium levels of surface IgM compared with Ramos, Daudi, MUTU-I and MUTU-61E (results not shown). Since each of the former group were insensitive to growth arrest, this suggested that although a high level of surface IgM did not guarantee anti-µ mAb-induced inhibition, it was a prerequisite for sensitivity.
Although initial studies were performed on the Ramos line, several Ramos sub-lines also exist. Two of these, RA.1 (a direct EBV transformant of the original Ramos), and EHRB (a more lymphoblastoid cell type) were assessed for anti-µ mAb-induced growth arrest. While RA.1 cells behaved in a similar manner to the parent line, EHRB cells were found to be particularly sensitive to growth arrest (data not shown) and furthermore succumbed to apoptosis over a period of 24 h in culture with anti-Fcµ mAb (Table 1) . EHRB cells were selected for almost all subsequent work. Ramos cells and sublines also have the advantage of being FcR-negative, and so in binding studies whole IgG could be used without interference from Fc:FcR interactions.
Growth inhibition with pairs of anti-Fcµ mAb
Crossblocking studies showed that the anti-Fcµ mAb M15/8 and ZL7/5 blocked the binding of each other and so bound to identical or overlapping epitopes on the Since mAb are directed to a single epitope on the Fcµ region, the most likely explanation for the enhanced response seen with non-crossblocking pairs, is that they crosslink the surface IgM more extensively. This interpretation would be consistent with the potent inhibition of growth seen with polyclonal anti-µ Ab ( Figure  1 ) and suggest that Daudi cells require a higher degree of crosslinking than EHRB in order to generate inhibitory signals.
Growth inhibition with anti-Fcµ multimers
As an additional method of investigating the role of crosslinking, the performance of Fab′ (univalent), F(ab′) 2 (bivalent) and F(ab′) 3 (trivalent) prepared from the anti-Fcµ mAb M15/8 were compared on EHRB cells. The results are shown in Figure 3 and demonstrate that increasing mAb valency resulted in increased growth inhibition. Thus Fab′ fragments were ineffective, F(ab′) 2 fragments were comparable to the parent IgG, and the F(ab′) 3 species was by far the most effective inhibitor. The insert in Figure 3 shows the level of DNA fragmentation achieved as a result of cells entering apoptosis when cultured with the different anti-µ mAb fragments. The trivalent F(ab′) 3 induced the highest level of DNA fragmentation. This result was confirmed by measuring the extent of apoptosis in each culture using the method of Nicoletti et al (1991) (Table 1) , which showed that the increasing growth inhibition correlated with an increase in the level of apoptosis induced, with the M15/8 Fab′, F(ab′) 2 and F(ab′) 3 fragments giving 6%, 20% and 40% apoptosis. In addition, several other criteria of apoptosis, including annexin V positivity, chromatin condensation, cell shrinkage and apoptotic body formation, were observed (results not shown). Cells were incubated with treatment antibody as described below and the level of apoptosis assessed by propridium iodide analysis. The anti-Fcµ mAb used was M15/8. a,b Cells were incubated with mAb at 1 µg ml -1 for 48 h. c Cells were incubated with 10 µg ml -1 anti-Fcµ mAb for 15 min, then washed and sheep anti-mouse IgG added for 48 h as described in Figure 5 . d Values represent mean ± SD for three experiments.
Effect of hyper-crosslinking on growth inhibition
As an alternative approach to demonstrate the effect of crosslinking IgM on B-cell growth, we used a layer of polyclonal Ab to extensively crosslink the primary mAb once it had bound to the cell surface. This is termed hyper-crosslinking. The protocol used in these experiments was to allow primary mAb (10 µg ml -1 ) to bind to the cell surface for 15 min, and then to remove the cells from excess mAb by centrifugation before adding the secondary polyclonal anti-mouse IgG Ab. The effect of hyper-crosslinking anti-Fcµ mAb was determined for both EHRB and Daudi cells, and the results are shown in Figure 4 . In EHRB cells, hypercrosslinking was extremely effective at inducing growth arrest ( Figure 4A ), thus while the anti-Fcµ mAb alone resulted in a maximum of 20% inhibition, in the presence of the hypercrosslinking Ab it was increased to greater than 90%. This enhanced growth inhibition was associated with an increase in the level of apoptosis from 6% to 43% (Table 1) The effect of domain specificity of anti-IgM mAb on growth inhibition
In the experiments described so far, the mAb used have been directed to epitopes present in the Fc region of the µ-chain (Cµ2-Cµ4 domains). We have previously reported (Zhang et al, 1995 ) that compared with these, those mAb recognizing epitopes present in the Fab arms of the IgM molecule (anti-Fdµ, anti-L chain, and anti-Id mAb) were comparatively poor in their ability to transduce growth inhibitory signals in Burkitt's cell lines. The results were confirmed and are represented in Figure 5 . The two anti-Fdµ mAb, XG9 and M-2E6, reduced growth by up to 25%, compared with 65% for anti-Fcµ mAb. The anti-λ mAb, Mc24/1C6 and M15/2, were also poor at causing growth inhibition as were three mAb specific for the EHRB (Ramos) idiotype, ZL16/1, ZL16/3, and ZL16/11. Crossblocking studies (results not shown) revealed that two of the anti-Id mAb (ZL16/1 and ZL16/3) recognized the same or proximal epitopes on surface IgM, but that the third (ZL16/11) recognized a distinct epitope. In growth arrest assays a mixture of either of the two non-crossblocking pairs, ZL16/1 + ZL16/11 or ZL16/3 + ZL16/11, unlike the single reagents or the crossblocking pair (ZL16/1 + ZL16/3), gave very effective growth inhibition of up to 70%. To determine whether the inhibitory activity of the single anti-Fdµ, anti-L chain or anti-Id mAb could be increased, the effect of hyper-crosslinking these reagents was investigated. The results in Figure 6 show that all types of anti-IgM mAb were highly effective at inducing growth inhibition when hyper-crosslinked by a second layer of polyclonal Ab.
Stoichiometry and affinity of mAb binding
We next determined the level of binding of 125 I-labelled mAb to EHRB cells; the plots in Figure 7A show the results obtained with representative mAb of each specificity. IgG from the three antiFcµ mAb and the two anti-Fdµ mAb gave similar saturation curves and levels of binding, with between 15 and 20 × 10 4 molecules of mAb binding to each cell. The binding affinities, estimated from these curves, were also similar at around 1 × 10 9 M -1 . Surprisingly, however, IgG from three anti-Id mAb and the anti-λ chain mAb gave maximum levels 
DISCUSSION
In this work we have investigated the ability of various anti-IgM mAb to induce growth arrest and apoptosis of a number of Burkitt's cell lines. The preliminary screening showed that of eight lines tested, only two, Ramos and Mutu-1, were sensitive to growth inhibition by anti-Fcµ mAb, and that Daudi cells, although not sensitive to anti-Fcµ mAb, showed inhibition in response to polyclonal anti-IgM. The differential sensitivity of the lines to anti-IgM inhibition probably relates to a number of factors. George et al (1993) have demonstrated that surface receptor number and density are important criteria in B-cell signalling. Our results showing that anti-µ Ab, whether polyclonal or monoclonal, was unable to induce growth inhibition in any of the low/medium IgM-expressing cell lines tested (Namalwa, Raji, Bristol-8 and Nalm-6), support this observation. This is in contrast to the reports from Rudich et al (1988) and Mongini et al (1992) who demonstrated that BCRinduced growth inhibition is much less dependent on receptor density than is B-cell activation. The insensitivity of some of the lines may also be related to their differentiation stage, as it is known that BCR ligation only signals for inhibition at certain stages during B-cell development, and may reflect the levels of anti-and proapoptotic proteins present. The EBV status of the cells (Gregory et al, 1991) and whether or not they possess FcR may also influence their sensitivity to growth inhibition and apoptosis. The Ramos EHRB sub-line selected for the main part of the project was exquisitely sensitive to anti-IgM-mAb-induced growth arrest and had the advantage that it did not express FcR, and so the inhibitory response could not be influenced by FcR:Fc interactions.
The two principle findings of the study were: 1) that the more surface IgM was crosslinked by mAb, the more effective was the resultant growth arrest and apoptosis; and 2) that the ability of a single mAb to induce crosslinking was highly dependent on epitope specificity. A range of experiments using anti-IgM mAb (single or cocktails), polyclonal anti-µ Ab, and hyper-crosslinking, all showed that growth arrest of B-cell lines was highly dependent on the extent of IgM crosslinking. These observations were confirmed by varying the valency of the mAb by using Fab′, F(ab′) 2 and F(ab′) 3 derivatives from anti-Fcµ mAb. Here the progressive increase in valency resulted in a corresponding decrease in cell proliferation, presumably as a result of more efficient BCR-crosslinking on the cell surface. Furthermore, we were able to show that cells treated with a trivalent F(ab′) 3 anti-µ derivative underwent extensive DNA fragmentation indicating induction of apoptosis (insert to Figure 3) . Interestingly, the ability of single mAb to mediate IgM crosslinking activity was dependent on their epitope specificity. Thus, mAb directed at the Fc region (Cµ2-Cµ4 domains) of surface IgM were much more effective at crosslinking B-cell IgM and inducing growth arrest, than were those directed at Fab region (anti-L chain, anti-Id and anti-Fdµ) of this molecule. Only when these latter mAb were hyper-crosslinked with polyclonal antimouse IgG did they cause appreciable growth arrest and apoptosis. Binding studies showed that this difference in function was not related to any marked disparity in the affinity of the mAb studied which were all in the range 1-4 × 10 9 M -1 ( Figure 6 ). In view of the results showing the importance of crosslinking in achieving growth inhibition, this probably relates to the intrinsic crosslinking capacity of the mAb, and depends on whether the anti-Fc and antiFab mAb bind to surface IgM bigamously or monogamously (Elliot et al, 1987) . mAb that bind bigamously, with epitopes or adjacent BCR complexes, form effective inter-BCR crosslinks, and those that bind monogamously, with the epitopes on a single surface IgM molecule, have poor crosslinking capacity. Rudich et al (1988) have provided evidence using immunoelectron microscopy that whereas the anti-Fdµ mAb XG9, used in this study, binds in a predominantly monogamous manner, an anti-Fcµ mAb, 1G6, binds predominantly bigamously. This could explain the inefficacy of XG9 in our assays and supports the hypothesis that bigamous binding is a requirement for BCR-induced growth inhibition. Grafton et al (1997) have recently published a study using a large panel of anti-IgM mAb recognizing the Cµ2-Cµ4 domains of the Fc region. They show that most of these mAb were able to induce growth inhibition; interestingly, although the panel did not include any mAb recognizing the anti-Fdµ region (Cµl domain), two anti-Id mAb in the panel failed to cause growth inhibition.
Although initially the lack of efficacy of the anti-L chain and anti-Id mAb was also attributed to a predominantly monogamous type binding, the results of the 125 I-labelled mAb binding experiments suggested an alternative explanation (Figure 7) . The maximum level of binding to EHRB cells obtained with IgG from the anti-L chain and anti-Id mAb was twice that obtained with the anti-Fcµ and anti-Fdµ mAb. Similar results were obtained with anti-Id mAb on Daudi cells and anti-L chain mAb on Namalwa cells. Assuming that the stoichiometry of anti-Fdµ and anti-Fcµ mAb binding to surface IgM molecule is 1:1, this suggests that two molecules of anti-L chain or anti-Id mAb were bound per surface IgM, and therefore favours the idea that their binding was predominantly univalent rather than bivalent, and that this is the reason for their poor growth inhibitory capacity. The comparison of the binding of F(ab′) 2 and Fab′ fragments (Figure 7 ) was consistent with this interpretation, since, in contrast to the results obtained with fragments from the anti-Fcµ mAb M15/8, Fab′ and F(ab′) 2 from anti-L chain mAb gave a similar value for maximum binding and binding affinity.
In view of the therapeutic success of anti-Id mAb in certain Bcell malignancies (Vuist et al, 1994; Racila et al, 1995; Tutt et al, 1998) , the inability of any of the three anti-Ramos Id mAb (and two for Daudi) to cause growth inhibition in vitro was somewhat surprising. This is particularly important because there is growing support for the idea that a number of therapeutic anti-lymphoma mAb, including anti-Id and anti-CD20, may be operating via a direct signalling route, rather than by the recruitment of cytotoxic effector cells (Tutt et al, 1998) . However, our results showed that irrespective of the ability of an individual mAb to induce growth inhibition, after hyper-crosslinking all mAb were equally potent. The ability of anti-Id mAb to induce transmembrane signalling and growth arrest in vivo is probably dependent on a number of factors other than their intrinsic crosslinking activity, which we have measured. For example, we can expect that FcR-bearing effector cells might play an important role in delivering hyper-crosslinking to anti-Id mAb-coated target cells. In this situation many FcRcarrying cells such as NK-cells, monocytes, neutrophils, endothelial cells or perhaps even B-cells would be effective at delivering cytotoxic signal. Thus effector cells would not necessarily need to be cytotoxic in themselves, but would simply need to deliver a multivalent array of FcR to hyper-crosslink the BCR. In support of this suggestion, recent work from Shan et al (1998) shows that the ability of another apoptosis-inducing mAb, anti-CD20, is markedly enhanced by the addition of FcR-bearing effector cells to the cultures. The presence of FcR-bearing cells has also been shown to enable a mAb recognizing CD79β, a signalling component of the BCR, to induce inhibitory signals (Van Kooten et al, 1997) . The results presented here show that in vitro most anti-Id mAb are particularly ineffective at crosslinking the BCR to mediate growth arrest, suggesting that their success in vivo probably require an additional form of crosslinking.
